Patient noncompliance as the cause of skin toxicity in capecitabine therapy
https://doi.org/10.17650/2782-3202-2022-2-3-55-58
Abstract
When using capecitabine, manifestations of toxicity in the form of palmar-plantar dysesthesia, redness, excessive sensitivity and peeling of the skin of the palms and feet are well known. However, in the scientific literature available to us, we did not find a single case of skin toxicity with capecitabine, in contrast to targeted therapy, for which skin manifestations are very characteristic. The dermal toxicity described in this paper developed as a result of patient noncompliance. These side effects reduced the adherence to therapy: the next courses of chemotherapy were postponed.
About the Authors
L. M. Kogoniya
M.F. Vladimirsky Moscow Region Scientific Research Clinical Institute;
“Clinic K+31” JSC
Russian Federation
Russian Federation
Lali M. Kogoniya
61/2 Shchepkina St., Moscow 129110,
Bld. 4, 42 Lobachevskogo St., Moscow 119415
K. E. Borisov
“Clinic K+31” JSC
Russian Federation
Russian Federation
Bld. 4, 42 Lobachevskogo St., Moscow 119415
K. I. Ershova
“Clinic K+31” JSC
Russian Federation
Russian Federation
Bld. 4, 42 Lobachevskogo St., Moscow 119415
References
1. Khobeysh M.M., Monakhov K.N. Daivobet – a newer highly effective preparation for external treatment of psoriasis of the palms and the soles. Klinicheskaya dermatologiya i venerologiya = Russian journal of clinical dermatology and venerology 2008;6(1):41–5. Available at: https://medi.ru/info/5518.
2. Lacouture M.E. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6(10):803–12. DOI: 10.1038/nrc1970
3. Pomerantz G., Mirvish E.D., Geskin L.J. Cutaneous reactions to epidermal growth factor inhibitors. J Drugs Dermatol 2010;9(10):1229–34.
4. Common Terminology Criteria for Adverse Events. Version 4.03. US Department of Health and Human Services, National Institutes of Health, NCI, Bethesda, MD, 2010. Available at: http://evs.nci.nih.gov/ftpl/CTCAE.4.03.2010-06-14.
5. Dy G.K., Adjei A.A. Understanding, recognizing and managing toxicities of targeted anticancer therapies. CA Cancer J Clin 2013;63(4):249–79. DOI: 10.3322/caac.21184
6. Kogoniya L.M., Mazurin V.S., Ilnitskaya O.V. et al. Palmar-and-plantar erythrodysesthesia is a series complications after capecitabin: our own experience. Almanah klinicheskoy meditsiny = Almanac of Clinical Medicine 2013;28:37–40.
7. Nagore E., Insa A., Sanmartín O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia (’hand-foot’) syndrome. Incidence, recognition and management. Am J Clin Dermatol 2000;1(4):225–34.
8. Dikaya L.A. Communicative competence of clinical psychologist. A study guide. Rostov-on-Don: Izdatelstvo Yuzhnogo federalnogo universiteta, 2016. 108 p. Available at: https://znanium.com/catalog/product/991896.
Review
For citations:
Kogoniya L.M., Borisov K.E., Ershova K.I. Patient noncompliance as the cause of skin toxicity in capecitabine therapy. MD-Onco. 2022;2(3):55-58. (In Russ.) https://doi.org/10.17650/2782-3202-2022-2-3-55-58
Views:
343
Email this article 